---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066946"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:48:50.258080+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences Q1 2025 net loss $8.8M; cash $91M; pipeline data expected in 2025

## Summary
- Net loss $8.8M ($1.17/diluted share) vs $9.1M in Q1 2024; revenue from Gilead collaboration $9.4M (up from $5.8M).
- Cash, equivalents and marketable securities $91.0M as of March 31, 2025; projected to fund operations into mid-2026.
- R&D expenses $14.9M (up from $11.9M) driven by ABI-6250 and ABI-5366; G&A $4.5M (slight decrease from $4.6M).
- Interim Phase 1b data for HSV candidates ABI-5366 and ABI-1179 expected in fall 2025; Phase 1a data for HDV candidate ABI-6250 in Q3 2025.
- Phase 1b data for HBV candidate ABI-4334 (400 mg cohort) expected in H1 2025.

## SEC filing metadata
- accession: 0000950170-25-066946
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017025066946/0000950170-25-066946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017025066946/asmb-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066946
- JSON: https://secwatch.observer/filing/0000950170-25-066946.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.